HRP20110570T1 - Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora - Google Patents

Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora Download PDF

Info

Publication number
HRP20110570T1
HRP20110570T1 HR20110570T HRP20110570T HRP20110570T1 HR P20110570 T1 HRP20110570 T1 HR P20110570T1 HR 20110570 T HR20110570 T HR 20110570T HR P20110570 T HRP20110570 T HR P20110570T HR P20110570 T1 HRP20110570 T1 HR P20110570T1
Authority
HR
Croatia
Prior art keywords
disorder
compound
dementia
disorders
composition
Prior art date
Application number
HR20110570T
Other languages
English (en)
Inventor
Mazurov Anatoly
Miao Lan
Xiao Yun-De
Original Assignee
Targacept
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept filed Critical Targacept
Publication of HRP20110570T1 publication Critical patent/HRP20110570T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Spoj N-(5-klorofuran-2-ilkarbonil)-3,7-diazabiciklo[3.3.0]oktan, ili neka njegova farmaceutski prihvatljiva sol. Patent sadrži još 8 patentnih zahtjeva.

Claims (9)

1. Spoj N-(5-klorofuran-2-ilkarbonil)-3,7-diazabiciklo[3.3.0]oktan, ili neka njegova farmaceutski prihvatljiva sol.
2. Spoj prema zahtjevu 1, za upotrebu u tretiranju poremećaja središnjeg živčanog sustava.
3. Farmaceutska kompozicija, koja kao aktivni sastojak sadrži terapeutski efikasnu količinu nekog spoja prema zahtjevu 1 ili 2, i jedan ili više farmaceutski prihvatljivih razblaživača, ekscipijenata i/ili inertnih nosača.
4. Farmaceutska kompozicija prema zahtjevu 3, u kojoj se N-(5-klorofuran-2-ilkarbonil)-3,7-diazabiciklo[3.3.0]oktan, ili neka njegova farmaceutski prihvatljiva sol nalazi u opsegu doze od oko 100 mg/kg do oko 1 mg/kg na dan.
5. Upotreba spoja prema zahtjevu 1 ili 2, ili kompozicije prema zahtjevu 3 ili 4, za proizvodnju lijeka za tretman poremećaja središnjeg živčanog sustava.
6. Spoj prema zahtjevu 2, kompozicija prema zahtjevima 3 ili 4, ili upotreba prema zahtjevu 5, gdje se poremećaji biraju iz skupine koju čine neusaglašenost memorije uslijed starenja, blaga kognitivna neusaglašenost, pre-senilna demencija (rani početak pojave Alzheimerove bolesti), senilna demencija (demencija Alzheimerovog tipa), demencija sa Lewyjevim tijelima, vaskularna demencija, Alzheimerova bolest, moždani udar, kompleks AIDS demencije, poremećaj smanjenja pažnje, kognitivni deficit, poremećaj hiperaktivnosti uslijed smanjenja pažnje, disleksija, shizofrenija, poremećaji shizofrenog oblika i shizoafektivni poremećaji.
7. Spoj, kompozicija ili upotreba prema zahtjevu 6, gdje se poremećaj bira iz skupine koju čine blaga do umjerena demencija Alzheimerovog tipa, blaga kognitivna neusaglašenost i neusaglašenost memorije uslijed starenja.
8. Spoj, kompozicija ili upotreba prema zahtjevu 6, gdje poremećaj predstavlja poremećaj smanjenja pažnje ili poremećaj hiperaktivnosti uslijed smanjenja pažnje.
9. Spoj, kompozicija ili upotreba prema zahtjevu 6, gdje poremećaj predstavlja shizofrenija, poremećaj shizofrenog oblika, kognitivni deficit ili shizoafektivni poremećaj.
HR20110570T 2006-11-02 2011-08-02 Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora HRP20110570T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02
PCT/US2007/083330 WO2008057938A1 (en) 2006-11-02 2007-11-01 Nicotinic acetylcholine receptorsub-type selective amides of diazabicycloalkanes

Publications (1)

Publication Number Publication Date
HRP20110570T1 true HRP20110570T1 (hr) 2011-09-30

Family

ID=39233054

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110570T HRP20110570T1 (hr) 2006-11-02 2011-08-02 Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora

Country Status (33)

Country Link
US (6) US8114889B2 (hr)
EP (2) EP2284171B1 (hr)
JP (2) JP5539723B2 (hr)
KR (2) KR101415705B1 (hr)
CN (4) CN102942569B (hr)
AR (2) AR063451A1 (hr)
AT (2) ATE509022T1 (hr)
AU (2) AU2007317433B2 (hr)
BR (2) BRPI0717930A2 (hr)
CA (1) CA2663925C (hr)
CL (1) CL2007003155A1 (hr)
CO (1) CO6180435A2 (hr)
CY (1) CY1112374T1 (hr)
DK (1) DK2094703T3 (hr)
ES (2) ES2395157T3 (hr)
HK (2) HK1133260A1 (hr)
HR (1) HRP20110570T1 (hr)
IL (2) IL197618A (hr)
MX (1) MX2009004801A (hr)
MY (2) MY156730A (hr)
NO (1) NO20091251L (hr)
NZ (2) NZ587847A (hr)
PE (2) PE20081441A1 (hr)
PL (1) PL2094703T3 (hr)
PT (1) PT2094703E (hr)
RS (1) RS51834B (hr)
RU (2) RU2448969C2 (hr)
SA (1) SA07280584B1 (hr)
SI (1) SI2094703T1 (hr)
TW (3) TWI454262B (hr)
UA (2) UA98944C2 (hr)
UY (1) UY30686A1 (hr)
WO (1) WO2008057938A1 (hr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
EP2257549A1 (en) * 2008-03-05 2010-12-08 Targacept Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
ES2383246T3 (es) 2008-06-05 2012-06-19 Glaxo Group Limited 4-amino-indazoles
US8536169B2 (en) 2008-06-05 2013-09-17 Glaxo Group Limited Compounds
ES2445199T3 (es) 2008-06-05 2014-02-28 Glaxo Group Limited Derivados de benzpirazol como inhibidores de PI3-quinasas
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
US20110263629A1 (en) * 2008-09-05 2011-10-27 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8575162B2 (en) 2009-04-30 2013-11-05 Glaxosmithkline Intellectual Property Development Limited Compounds
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
HUE033352T2 (en) 2009-11-18 2017-11-28 Suven Life Sciences Ltd Bicyclic compounds as alpha4-beta2 nicotinic acetylcholine receptor ligands
ES2552932T3 (es) 2009-12-29 2015-12-03 Suven Life Sciences Limited Ligandos del receptor nicotínico neuronal de la acetilcolina alfa4beta2
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
HUE036117T2 (hu) 2013-11-26 2018-06-28 Hoffmann La Roche Oktahidro-ciklobuta[1,2-C;3,4-C']dipirrol származékok, mint autotaxin inhibitorok
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
WO2016064759A1 (en) 2014-10-20 2016-04-28 Oyster Point Pharma, Inc. Methods of treating ocular conditions
UA123362C2 (uk) 2015-09-04 2021-03-24 Ф. Хоффманн-Ля Рош Аг Феноксиметильні похідні
CN107614505B (zh) * 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
WO2017050791A1 (en) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
AU2016328535A1 (en) 2015-09-24 2017-11-09 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
WO2017177024A1 (en) 2016-04-07 2017-10-12 Oyster Point Pharma, Inc. Methods of treating ocular conditions
AU2018233079B9 (en) 2017-03-16 2021-07-22 F. Hoffmann-La Roche Ag Heterocyclic compounds useful as dual ATX/CA inhibitors
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
PL3448859T3 (pl) 2017-03-20 2020-02-28 Forma Therapeutics, Inc. Kompozycje pirolopirolu jako aktywatory kinazy pirogronianowej (PKR)
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼrの活性化
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
DE69416869T2 (de) * 1993-12-29 1999-07-01 Pfizer Diazabicyclische neurokinin antagonisten
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
MXPA02005884A (es) * 1999-12-14 2002-10-23 Neurosearch As Heteroaril-diazabicicloalcanos novedosos.
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
AU2002320958B2 (en) 2001-07-06 2008-02-28 Neurosearch A/S Novel compounds, their preparation and use
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
AU2004215658B2 (en) * 2003-02-27 2010-06-24 Neurosearch A/S Novel diazabicyclic aryl derivatives
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
DE602005004144T2 (de) * 2004-06-09 2009-01-29 F. Hoffmann-La Roche Ag Octahydropyrroloä3,4-cüpyrrolderivate und deren verwendung als antivirale mittel
DE602005013671D1 (de) 2004-07-22 2009-05-14 Cumbre Pharmaceuticals Inc (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen
EP1893212B1 (en) * 2005-05-13 2013-10-16 Lexicon Pharmaceuticals, Inc. Multicyclic compounds and methods of their use
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
ES2395212T3 (es) 2013-02-11
TW200826935A (en) 2008-07-01
UA98944C2 (ru) 2012-07-10
TWI454262B (zh) 2014-10-01
CN102942569A (zh) 2013-02-27
ATE545646T1 (de) 2012-03-15
AU2010219323A1 (en) 2010-09-30
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
CN102838605B (zh) 2017-04-26
PL2094703T3 (pl) 2011-10-31
BRPI0717930A2 (pt) 2011-05-10
US8921410B2 (en) 2014-12-30
US8859609B2 (en) 2014-10-14
CL2007003155A1 (es) 2008-05-16
ATE509022T1 (de) 2011-05-15
CN102020646B (zh) 2013-11-13
CN102020646A (zh) 2011-04-20
CO6180435A2 (es) 2010-07-19
TWI404532B (zh) 2013-08-11
CN102942569B (zh) 2015-10-28
IL209026A0 (en) 2011-01-31
AU2007317433A1 (en) 2008-05-15
US20100081683A1 (en) 2010-04-01
AR079840A2 (es) 2012-02-22
CA2663925A1 (en) 2008-05-15
US20100173932A1 (en) 2010-07-08
SI2094703T1 (sl) 2011-07-29
UY30686A1 (es) 2009-08-03
PT2094703E (pt) 2011-07-22
IL209026A (en) 2014-03-31
MY145602A (en) 2012-03-15
RU2517693C2 (ru) 2014-05-27
CA2663925C (en) 2015-04-21
HK1133260A1 (en) 2010-03-19
AR063451A1 (es) 2009-01-28
IL197618A0 (en) 2009-12-24
RU2009120674A (ru) 2010-12-10
NZ587847A (en) 2011-09-30
SA07280584B1 (ar) 2010-11-02
US20120289572A1 (en) 2012-11-15
JP2010509230A (ja) 2010-03-25
NZ575557A (en) 2011-01-28
EP2094703B1 (en) 2011-05-11
JP5739398B2 (ja) 2015-06-24
JP2013056919A (ja) 2013-03-28
WO2008057938A1 (en) 2008-05-15
MY156730A (en) 2016-03-15
UA106718C2 (uk) 2014-10-10
NO20091251L (no) 2009-05-28
ES2395157T3 (es) 2013-02-08
CN101528745B (zh) 2011-09-14
EP2284171A1 (en) 2011-02-16
TW201114424A (en) 2011-05-01
TWI405763B (zh) 2013-08-21
EP2284171B1 (en) 2012-02-15
JP5539723B2 (ja) 2014-07-02
KR20090074051A (ko) 2009-07-03
IL197618A (en) 2013-09-30
RS51834B (en) 2012-02-29
EP2094703A1 (en) 2009-09-02
US8268860B2 (en) 2012-09-18
DK2094703T3 (da) 2011-08-29
TW201305176A (zh) 2013-02-01
HK1149751A1 (en) 2011-10-14
US20130005789A1 (en) 2013-01-03
MX2009004801A (es) 2009-07-31
PE20081441A1 (es) 2008-10-30
US8114889B2 (en) 2012-02-14
US9580434B2 (en) 2017-02-28
CN102838605A (zh) 2012-12-26
KR101415705B1 (ko) 2014-07-04
CY1112374T1 (el) 2015-12-09
RU2448969C2 (ru) 2012-04-27
KR20100124356A (ko) 2010-11-26
US20160039833A1 (en) 2016-02-11
PE20110671A1 (es) 2011-10-20
BRPI0722387A2 (pt) 2023-02-23
US20150080576A1 (en) 2015-03-19
AU2007317433B2 (en) 2012-05-10
RU2009138600A (ru) 2011-04-27

Similar Documents

Publication Publication Date Title
HRP20110570T1 (hr) Amidi diazabicikloalkana selektivni na podvrstu nikotinskih acetilkolinskih receptora
RU2012140148A (ru) (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
ATE458736T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken, verfahren zu deren herstellung und pharmazeutische zusammensetzungen,die diese enthalten
RU2008148325A (ru) Полиморфные формы(2s)-(4е)-n-метил-5-(3-изопропоксипиридин)ил) 4-пентен-2амина для лечения расстройств центральной нервной системы
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
EP1820503A3 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
WO2009050242A3 (de) Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
DK1673092T3 (da) Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
GEP20084417B (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
NO20091888L (no) Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav
DE602005008633D1 (de) Imidazoä1,5aütriazoloä1,5dübenzodiazepin-derivative zur behandlung kognitiver störungen
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
MXPA05009719A (es) Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
RU2005141060A (ru) Метаболит кветиапина
US20210198218A1 (en) Compounds for therapeutic use
TW200635906A (en) Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
SI1556045T1 (sl) Derivati 4-aminopiperidina, postopek izdelave in uporaba v medicini
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
NO20084819L (no) Substituerte pyrazinonderivater for anvendelse som en medisin